Categories: News

Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Detroit, Michigan–(Newsfile Corp. – March 23, 2021) – Alpha Cognition Inc. (“ACI”), a biopharmaceutical company focused on neurological disorders, with near term commercialization potential for its Alpha-1062 Alzheimer’s drug announced today that Dr. Fred Sancilio, ACI’s President will be presenting at the Benzinga Biotech Small Cap Conference on March 24th, 2021 at 10:55 AM ET. The presentation will cover all key aspects of ACI’s business including a summary of the de-risked ALPHA-1062 clinical program with its accelerated path to near term FDA approval and its other market opportunities that can address areas of high unmet medical needs.

We invite our shareholders, and all interested parties to register for our presentation at the spectator link for the event: https://www.benzinga.com/events/small-cap/biotech/

About Alpha Cognition Inc.

Alpha Cognition, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates targeting neurological diseases.

Alpha-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with minimal gastrointestinal side effects and novel routes of administration. Alpha-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.

Alpha-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia and in a nasal spray formulation to treat traumatic brain injury.

Alpha-602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment neurodegenerative diseases has been patented by ACI and granted an Orphan Drug Designation.

For further information:

Bristol Investor Relations
Stefan Eftychiou
905 326 1888 ext 6
stefan@bristolir.com
https://www.alphacognition.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/78257

Staff

Recent Posts

Edison Issues Report On Global Fashion Group (GFG)

London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on Global Fashion…

49 minutes ago

Edison Issues Report on DUG Technology (DUG)

London, United Kingdom--(Newsfile Corp. - June 10, 2025) - Edison issues report on DUG Technology…

49 minutes ago

Panacea Healthcare Solutions to Host Webinar on Aligning Strategic Pricing and Payer Contract Modeling to Maximize Financial Performance

ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- Panacea Healthcare Solutions, a leading provider of financial,…

2 hours ago

Uniting to Improve Wellbeing and Social Capital: Bipartisan Solutions to End Social Isolation and Loneliness in America

A Capitol Hill Convening to Advance Cross-Sector Strategies that Rebuild Human Connection and Strengthen Communities WASHINGTON,…

2 hours ago

Smart Healthcare Is Taking Over. Here’s Where the Money’s Headed

Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025…

2 hours ago

LeanTaaS Launches iQueue for Surgical Clinics, Delivering the Industry’s First End‑to‑End Surgical Coordination Platform

Unveiled live at Transform, LeanTaaS' hospital operations summit, the new product embeds key case building, managing,…

2 hours ago